X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Research & Development

Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. Circuit Therapeutics’ key technology, optogenetics, allows the control of individual nerve cells and circuits within the brain enabling their functional identification and characterization. The combination of optogenetics and sophisticated molecular technologies provides an unprecedented level of focus to identify novel drug targets and approaches for drug development.

The new insights enabled by circuit-based analysis provide fundamentally differentiated approaches to understanding and treating brain disorders, which have otherwise been difficult to address.

Under the terms of the agreement the research and development capabilities of the two companies will be brought together to provide novel avenues for drug discovery in a three-year research program.

Further details of the agreement are not disclosed.

“We are excited to work with Boehringer Ingelheim to utilize Circuit’s unique capabilities to advance drug discovery. The innovative and ambitious vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with Circuit’s innovative technologies makes an ideal partnership. We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients’ lives,” said Fred Moll, Chairman of Circuit Therapeutics.

“We are very enthusiastic about being able to work in a partnership with Circuit Therapeutics, one of the leading organizations in the field of circuit biology and optogenetics”, said Dr. Bernd Sommer, the head of neuroscience research at Boehringer Ingelheim. “We believe that, by working together to investigate maladaptive brain circuitry with this exciting approach, we will be able to obtain a better understanding of the neurobiological basis of human neuropsychiatric disorders, thereby allowing us to make a difference to science, disease and patients.”

About Circuit Therapeutics

Circuit Therapeutics is a privately held discovery stage biotechnology company based in Menlo Park, California. The company’s cutting edge technologies focused on neural circuits are being applied to enable new ways of drug discovery and development of direct therapeutic interventions across a broad range of indications.

Previous Post

Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration

Next Post

Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023
News

Randomness Drives Tumour Cells Response To Chemotherapy

10th March 2023
Featured

Animal Testing Could See An End With An Artificial Model

28th February 2023
Featured

Germany Rolls First CAR-T Push For Muscle Inflammation Cure

27th February 2023
Next Post

Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In